Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on June 9, 2025. The report details corporate governance actions taken at a Special Meeting of Stockholders held on the same date, including the redemption of preferred stock and amendments to the Company's Articles of Incorporation.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to a specific transaction:
- Preferred Stock Redemption: One share of Series A Preferred Stock was redeemed for aggregate consideration of $100, representing the original purchase price.
Material Changes
The following material changes were effected on June 9, 2025:
- Capital Structure Amendment: The Company increased its authorized shares of capital stock from 26,000,000 to 260,000,000.
- Common Stock Authorization: The authorized number of common shares (par value $0.001) was increased from 16,000,000 to 250,000,000.
- Preferred Stock Status: The one outstanding share of Series A Preferred Stock issued on April 17, 2025, was automatically redeemed upon the filing of this report.
Voting Results and Management Commentary
Stockholders approved the amendment to the Articles of Incorporation at the Special Meeting. The voting results were as follows:
- For: 547,138,179 shares
- Against: 457,549,494 shares
- Abstaining: 520,782 shares
- Broker Non-Votes: None
The holder of the Series A Preferred Stock was entitled to cast 1,000,000,000 votes. Per the stock terms, these votes were cast automatically in a "mirrored" proportion to the common stock votes cast "For" and "Against" the amendment. A proposal to adjourn the meeting to solicit additional proxies became moot following the approval of the amendment.
Investor Verification Checklist
- Verify the effective date of the Certificate of Amendment filed with the State of Nevada.
- Confirm the current outstanding share count following the redemption of the Series A Preferred Stock.
- Review the Company's capitalization table to understand the impact of the increased authorized share pool on potential future dilution.
- Check subsequent filings for any immediate issuance of shares from the newly authorized pool.